Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy

Abstract

Haematopoietic stem cell (HSC) gene therapy has demonstrated potential to treat many diseases. However, current state of the art requires sophisticated ex vivo gene transfer in a dedicated Good Manufacturing Practices facility, limiting availability. An automated process would improve the availability and standardized manufacture of HSC gene therapy. Here… (More)
DOI: 10.1038/ncomms13173

Topics

1 Figure or Table

Cite this paper

@inproceedings{Adair2016SemiautomatedCS, title={Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy}, author={Jennifer E Adair and Timothy R. Waters and Kevin G. Haworth and Sara P. Kubek and Grant D. Trobridge and Jonah Hocum and Shelly Heimfeld and Hans-Peter Kiem}, booktitle={Nature communications}, year={2016} }